• Nenhum resultado encontrado

Sao Paulo Med. J. vol.129 número4

N/A
N/A
Protected

Academic year: 2018

Share "Sao Paulo Med. J. vol.129 número4"

Copied!
1
0
0

Texto

(1)

Sao Paulo Med J. 2011; 129(4):277 277

COCHRANE HIGHLIGHTS

Laxatives or

methylnaltrexone for

the management of

constipation in palliative

care patients

Bridget Candy, Louise Jones, Margaret Lynn Goodman,

Robyn Drake, Adrian Tookman

The independent commentary was written by Ricardo

Tavares de Carvalho.

ABSTRACT

BACKGROUND: Constipation is common in palliative care; it can gener-ate considerable suffering due to the unpleasant physical symptoms. In the first Cochrane Review on effectiveness of laxatives for the manage-ment of constipation in palliative care patients, published in 2006, no conclusions could be drawn because of the limited number of evalua-tions. This article describes the first update of this review.

OBJECTIVE: To determine the effectiveness of laxatives or methylnal-trexone for the management of constipation in palliative care patients. CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW: We searched databases including MEDLINE and CENTRAL (The Cochrane Library) in 2005 and in the update to August 2010.

SELECTION CRITERIA: Randomized controlled trials (RCTs) evaluat-ing laxatives for constipation in palliative care patients. In the update we also included RCTs on subcutaneous methylnaltrexone; an receptor antagonist that is now licensed for the treatment of opioid-induced constipation in palliative care when response to usual laxative therapy is insufficient.

DATA COLLECTION AND ANALYSIS: Two authors assessed trial quality and extracted data. The appropriateness of combining data from the studies depended upon clinical and outcome measure homogeneity. MAIN RESULTS: We included seven studies involving 616 participants; all under-reported methodological features. In four studies the laxatives lactulose, senna, co-danthramer, misrakasneham, and magnesium hy-droxide with liquid paraffin were evaluated. In three methylnaltrexone. AUTHORS’ CONCLUSIONS: The 2010 update found evidence on laxa-tives for management of constipation remains limited due to insuf-ficient RCTs. However, the conclusions of this update have changed since the original review publication in that it now includes evidence on methylnaltrexone. Here it found that subcutaneous methylnaltrexone is effective in inducing laxation in palliative care patients with opioid-induced constipation and where conventional laxatives have failed. However, the safety of this product is not fully evaluated. Large, rigor-ous, independent trials are needed.

This is the abstract of a Cochrane Review published in the Cochrane

Database of Systematic Reviews (CDSR) 2011, Issue 2, DOI: DOI:

10.1002/14651858.CD003448.pub4 (www.thecochranelibrary.com). For

full citation and authors details see reference 1.

For Latin America and the Caribbean, the full text is freely available

from: http://cochrane.bvsalud.org/cochrane/show.php?db=reviews&mf

n=1839&id=CD003448&lang=pt&dblang=&lib=COC&print=yes

This section was edited under the responsibility of the Brazilian

Cochrane Center

REFERENCE

1. Candy B, Jones L, Goodman ML, Drake R, Tookman A. Laxatives or

methylnaltrexone for the management of constipation in palliative

care patients. Cochrane Database of Syst Rev. 2011;(1):CD003448.

COMMENTS

Opioid-induced constipation is one of the most common issues in pallia-tive care practice. However, rational use of laxapallia-tives tends to be effecpallia-tive treatment for most cases. Besides this, maintaining good hydration and avoiding remaining immobile, if possible, are strongly recommended. Methylnaltrexone is an opioid-receptor antagonist recently approved by the United States Food and Drug Administration (FDA) and has shown promising results in this group of patients. However, its high cost makes rational indication necessary, directed specifically towards cases that are resistant to other laxatives, with careful use and even with use in association.

There is still a lack of evidence from randomized controlled studies (RCTs). New RCTs would make it possible to better understand the risks, benefits and security issues of this new drug.

Ricardo Tavares de Carvalho. Scientific Director, National Academy of

Palliative Care (Academia Nacional de Cuidados Paliativos; ANCP), São

Referências

Documentos relacionados

he aim of the present study was to determine the incidence of diferent morphological and immunophenotypic subtypes of acute leukemia among patients referred to an

Cirurgia da insuiciência mitral no tratamento da insuiciência cardíaca avançada [revisão] [Mitral insuficiency surgery to treat advanced heart failure [review]]. Rev Bras

The aim here was to assess the prevalence of prediabetes among individuals at high risk of developing DM, and to seek variables relating to glucose intolerance (GI) among individuals

Frequency of the anti-glutamic acid decarboxylase immunological marker in patients with diabetes duration longer than three years in southern Brazil.. Sao Paulo

he liver specimens were obtained by means of percutaneous biopsy and were processed using optical microscopy and trans- mission electron microscopy (TEM). For optical microscopy, the

Sixteen hours before anesthesia, the patients were presented with a questionnaire including structured questions to identify patient characteristics (age, gender, race,

Considering that the accuracy of ER and PgR testing in breast carcinoma is extremely important in selecting the hormone ther- apy, the present study had the aim of

In this review, we discuss the main differences between direct and indirect stimuli, and the use of bronchial challenges in clinical prac- tice, especially for confirming